Skip to main content
HLB bioStep Co.,Ltd. logo

HLB bioStep Co.,Ltd. — Investor Relations & Filings

Ticker · 278650 ISIN · KR7278650007 KO Professional, scientific and technical activities
Open in API
Filings indexed 323 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country KR South Korea
Listing KO 278650

About HLB bioStep Co.,Ltd.

http://hlbbiostep.com/en/

HLB bioStep Co.,Ltd. is a non-clinical Contract Research Organization (CRO) that provides a range of testing services to pharmaceutical companies and bio ventures. The company's core services support new drug development and include efficacy testing, pharmacokinetic/toxicokinetic (PK/TK) studies, and toxicology evaluations. A key area of specialization is veterinary medicine; HLB bioStep is an institution approved to conduct non-clinical tests and clinical trials for veterinary drugs. It also offers consulting services for regulatory approval procedures. The company utilizes various platform technologies, such as cell-enzyme-based screening and xenograft assays, and provides a comprehensive 'One-Stop Service' that leverages its experience in building laboratory facilities.

Recent filings

Filing Released Lang Actions
주권매매거래정지해제 (액면병합 주권 변경상장)
Regulatory Filings Classification · 90% confidence The document is a brief notice in Korean regarding the lifting of a trading suspension (“주권매매거래정지해제”) for a specific stock on the KOSDAQ, citing regulatory rules and the effective date. It does not announce a delisting, earnings, or any financial statements, but is a routine regulatory announcement about trading status. This falls under the general “Regulatory Filings” catch-all category.
2026-05-15 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” (Quarterly Report) for the 15th period covering January 1, 2026 to March 31, 2026. It contains comprehensive financial statements, segment revenues, business overviews, risk management, and detailed notes—characteristics of a full interim/quarterly financial report rather than an announcement. Therefore, it is classified as an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 85% confidence The document is titled “임원ㆍ주요주주 특정증권등 소유상황보고서,” a mandatory disclosure of an officer/major shareholder’s holdings and changes in specific securities. It lists dates, share counts before and after transactions, and is filed with regulators (Korea Securities and Exchange Commission and Korea Exchange). This is a classic insider dealing/ownership report by a director or major shareholder, matching the Director’s Dealing category.
2026-05-11 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 92% confidence The document is a detailed large shareholding status report (“주식등의 대량보유상황보고서”) filed under Korean capital markets law, listing share ownership changes, percentages, reporting persons, dates, and reasons for change. It is not an AGM material, management report, earnings release, or regulatory publication notice but a direct notification of significant shareholding levels. This matches the Major Shareholding Notification category.
2026-05-11 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-05-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-05-08 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.